9.905
전일 마감가:
$9.90
열려 있는:
$9.544
하루 거래량:
1.90M
Relative Volume:
0.76
시가총액:
$1.60B
수익:
$246.03M
순이익/손실:
$-32.00M
주가수익비율:
-46.61
EPS:
-0.2125
순현금흐름:
$-16.78M
1주 성능:
+7.37%
1개월 성능:
+20.85%
6개월 성능:
+110.40%
1년 성능:
+207.76%
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
명칭
Xeris Biopharma Holdings Inc
전화
844-445-5704
주소
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
XERS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings Inc
|
9.905 | 1.60B | 246.03M | -32.00M | -16.78M | -0.2125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.33 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
627.97 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.26 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.34 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.74 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-12 | 재개 | H.C. Wainwright | Buy |
| 2024-11-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2023-08-28 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Craig Hallum | Buy |
| 2021-11-17 | 개시 | SVB Leerink | Outperform |
| 2021-10-29 | 개시 | H.C. Wainwright | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-02-18 | 개시 | Piper Sandler | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Leerink Partners | Outperform |
| 2018-07-16 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Xeris Biopharma Holdings Inc 주식(XERS)의 최신 뉴스
Why Xeris Biopharma Holdings Inc. (2B30) stock appeals to dividend investorsJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
40,465 Shares in Xeris Biopharma Holdings, Inc. $XERS Bought by Savvy Advisors Inc. - MarketBeat
Why Xeris Biopharma Holdings Inc. (2B30) stock is listed among top recommendations - newser.com
Is Xeris Biopharma Holdings Inc. stock undervalued vs historical averagesPortfolio Gains Report & Weekly Market Pulse Alerts - newser.com
Applying chart zones and confluence areas to Xeris Biopharma Holdings Inc.2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
Is a relief rally coming for Xeris Biopharma Holdings Inc. holdersQuarterly Portfolio Report & AI Powered Market Entry Strategies - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock could be top winner - newser.com
Can Xeris Biopharma Holdings Inc. stock maintain growth trajectory2025 Big Picture & Breakout Confirmation Trade Signals - newser.com
How higher bond yields impact Xeris Biopharma Holdings Inc. (2B30) stockMarket Risk Analysis & Real-Time Stock Entry Alerts - newser.com
Can Xeris Biopharma Holdings Inc. stock maintain operating marginsWatch List & Safe Capital Investment Plans - newser.com
How sentiment analysis helps forecast Xeris Biopharma Holdings Inc.July 2025 Sentiment & Stock Market Timing Techniques - newser.com
Is Xeris Biopharma Holdings Inc. (2B30) stock supported by strong fundamentalsQuarterly Trade Review & AI Forecast for Swing Trade Picks - newser.com
Xeris Biopharma (NASDAQ:XERS) Downgraded to Hold Rating by Zacks Research - MarketBeat
Y Intercept Hong Kong Ltd Acquires 291,696 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
What high frequency data says about Xeris Biopharma Holdings Inc.2025 Market WrapUp & Free Technical Confirmation Trade Alerts - newser.com
Xeris Biopharma Hits New 52-Week High of $10.03, Up 314.66% - Markets Mojo
Is Xeris Biopharma Holdings Inc. stock entering bullish territoryJuly 2025 Sentiment & Fast Exit Strategy with Risk Control - newser.com
Using R and stats models for Xeris Biopharma Holdings Inc. forecasting2025 Market Trends & Technical Confirmation Trade Alerts - newser.com
Xeris Biopharma (XERS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Detecting support and resistance levels for Xeris Biopharma Holdings Inc.Market Activity Recap & Accurate Technical Buy Alerts - newser.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Hits New 1-Year HighStill a Buy? - MarketBeat
Is Xeris Biopharma Holdings Inc. (2B30) stock cheap vs fundamentals2025 Market WrapUp & Daily Profit Maximizing Trade Tips - newser.com
Xeris Biopharma Hits New 52-Week High of $9.48, Up 297% Year-Over-Year - Markets Mojo
Oppenheimer Adjusts Price Target on Xeris Biopharma to $18 From $8, Maintains Outperform Rating - MarketScreener
What Xeris Biopharma Holdings (XERS)'s Strong Revenue Growth and Pipeline Advances Mean For Shareholders - simplywall.st
Xeris Biopharma Holdings Inc (XERS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):